A. Experimental design for the survival trial: 8 weeks old wild type mice were injected with GL261 cells to induce glioma formation and were assigned randomly to vehicle (n = 6), anti-CSF1 monoclonal antibody treatment (0.5mg ; n=6), temozolomide treatment (40mg/kg ; n=6) or temozolomide and anti-CSF1 mAb combination treatment (n = 6). Mice were weighed once daily until they developed symptoms or reached the trial endpoint. 